Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd. is a biotechnology company specializing in the development of cell therapies, particularly through its Allocetra™ platform targeting inflammatory diseases. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Jerusalem, Israel.

The company focuses on innovative treatments for inflammatory diseases using its proprietary Allocetra™ platform. In September 2017, Enlivex secured USD 8 mn in Series B funding from Hadasit Bio-Holdings Ltd. and Korea Investment Partners. The company has completed a total of 2 funding deals to date.

Oren Hershkovitz serves as the CEO. Enlivex Therapeutics Ltd. is dedicated to the development and commercialization of its proprietary cell therapy platform, Allocetra™, aimed at treating various inflammatory diseases. Allocetra™ employs a unique therapeutic mechanism that leverages the natural healing capabilities of macrophages to manage both acute conditions like sepsis and long-term inflammatory diseases such as osteoarthritis.

The therapy can be administered via systemic intravenous infusion or through targeted local injections, making it versatile for different medical situations. Enlivex's focus is on healthcare providers and clinical trial participants, targeting markets in North America, Europe, and parts of Asia, with clinical trials validating Allocetra™'s efficacy and safety across over 150 patients. Enlivex Therapeutics operates a revenue model centered around the development and eventual commercialization of its leading product, Allocetra™. Expected revenue streams will arise from partnerships with healthcare institutions and research organizations involved in clinical trials, alongside future sales following regulatory approvals.

The structure of these transactions will likely include direct agreements with hospitals and clinics, leveraging both B2B and direct-to-consumer channels once Allocetra™ is commercially available. Pricing strategies will align with the product's therapeutic value to ensure accessibility for healthcare providers and patients. Enlivex Therapeutics plans to leverage the recent USD 8 mn raised in Series B financing to advance its clinical pipeline and launch new products based on the Allocetra™ platform. The company aims to expand its reach into new geographic regions, specifically targeting additional markets in Europe and Asia by the end of 2023.

The capital raised in September 2017 will support these initiatives, enhancing their capacity to conduct further clinical trials and facilitating market entry for Allocetra™.